How is LAMA positioned in the GINA guidelines?
The GINA 2020 strategy recommends a stepwise approach to asthma management. As part of step…
How does the CAPTAIN study support the use of triple therapy in asthma?
CAPTAIN provides robust evidence to support, and better tailor, the use of FF 100/UMEC/VI and FF 200/UMEC/VI using a treatable traits based approach:
- FF 100/UMEC/VI to improve lung function and enable more patients to improve asthma control in those with symptoms on ICS/LABA
- FF 200/UMEC/VI to additionally reduce exacerbations in patients with symptoms on mid-dose ICS/LABA
How does the CAPTAIN study support the use of triple therapy in asthma?
Download this presentation
Related materials
Reference
- Lee L, et al. Lancet Respir Med, 2020.
Asthma Forward is a registered trade mark of the GSK group of companies.
©2022 GSK group of companies. All rights reserved.
SE-GBL-FVU-WCNT-200063 | December 2022